Annual Shareholder's Meeting 2024

Annual Shareholder's Meeting 2024

Financial Results First Quarter 2024

Financial Results First Quarter 2024

Pillars of growth

R&D

Heavy bet for R&D
as a future
growth engine

conocer +

R&D&i
R&D

Heavy bet on R&D
as a future
growth engine

find out more

R&D&i
Biosimilar de Enoxaparina

Biosimilars

A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.

find out more

Especialidades farmacéuticas

Pharmaceutical products

Diversified portfolio of innovative own and licensed products protected by patents.
 

find out more

Bemiparina

Low Molecular Weight Heparin

ROVI's principal product, a low-molecular-weight heparin developed in-house.
 

find out more

Fabricación a terceros

CDMO

High production capacity with four the manufacturing plants for prefilled syringes and oral solid forms.

find out more

Rovi en cifras

Rovi in figures

829.5 Mn€

Operatig revenuein 2023

420.2 Mn€

· 420.2 Mn € Specialty Pharmaceutical business Sales in 2023(+1% vs 2022)

64
countries

LMWH presence through strategic alliances with international partners

24.9 Mn€

R&D expenses in 2023 (+4% vs 2022)

409.3 Mn€

CDMO Sales in 2023 (+1% vs 2022)

42,85%

Porcentage of women on the   Boards of Directors

Information for investors

Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.

Go to Shareholders and Investors

Last news on Rovi 

(See all items)

Last annual report

annualreport1

Annual report 2023

Last regular
public information

annualreport1

Executive Summary